ArticleWorld journal of clinical oncology2011
Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies.
Article in World journal of clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silverOpen medicine (Warsaw, Poland) · 2021Article
- Organ-restricted vascular delivery of nanoparticles for lung cancer therapy.Advanced therapeutics · 2020Article
- Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors.Cancer research · 2018Article
- Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma.Oncology letters · 2018Article
- Current status of research and treatment for non-small cell lung cancer in never-smoking females.Cancer biology & therapy · 2017Review
- Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.The oncologist · 2017Article
- [Advances in the Research of Autophagy in EGFR-TKI Treatment and Resistance in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2016Review
- Mechanisms of resistance to EGFR tyrosine kinase inhibitors.Acta pharmaceutica Sinica. B · 2015Review
- [Clinical Research of EGFR and KRAS Mutation in Fine Needle Aspiration Cytology Specimens of Non-small Cell Lung Carcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015Article
- Immunotherapy for lung cancer: for whom the bell tolls?Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India.Lung India : official organ of Indian Chest Society · 2014Article
- Article
- Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies.World journal of gastroenterology · 2013Review
- Article
- Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia.BMC cancer · 2012Article
- EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Article
- Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices.Clinics (Sao Paulo, Brazil) · 2012Article
- Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Article
- Metastatic melanoma and vemurafenib: novel approaches.Rare tumors · 2012Article
- Endoplasmic reticulum calcium pumps and cancer cell differentiation.Biomolecules · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is currently the leading cause of cancer death in Western nations. Non-small cell lung cancer (NSCLC) represents 80% of all lung cancers, and adenocarcinoma is the predominant histological type. Despite the intensive research carried out on this field and therapeutic advances, the overall prognosis of these patients remains unsatisfactory, with a 5-year overall survival rate of less than 15%. Nowadays, pharmacogenetics and pharmacogenomics represent the key to successful treatment. Recent studies suggest the existence of two distinct molecular pathways in the carcinogenesis of lung adenocarcinoma: one associated with smoking and activation of the K-Ras oncogene and the other not associated with smoking and activation of the epidermal growth factor receptor (EGFR). The K-ras mutation is mainly responsible for primary resistance to new molecules which inhibit tyrosine kinase EGFR (erlotinib and gefitinib) and most of the EGFR mutations are responsible for increased tumor sensitivity to these drugs. This article aims to conduct a systematic review of the literature regarding the molecular pathways involving the EGFR, K-Ras and EGFR targeted therapies in NSCLC tumor behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.